Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)
Status:
Withdrawn
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and efficacy of fondaparinux in patients with
heparin-induced thrombocytopenia (HIT). The primary objective is to ensure that patients with
HIT who are treated with fondaparinux experience a prompt and complete recovery of their
platelet count, and the secondary objective is to determine if any new blood clots are formed
while receiving the fondaparinux and up to one month after study enrollment. This information
will be compared to a historical control.